Intracellular expression of human immunodeficiency virus type 1 (HIV-1) protease variants inhibits replication of wild-type and protease inhibitor- resistant HIV-1 strains in human T-cell lines

Journal of Virology

Volumn 70, Issue 11, 1996, Pages 7765-7772

  Junker, Uwe ^a   Escaich, Sonia ^a,d   Plavec, Ivan ^a   Baker, Jenny ^a   McPhee, Fiona ^b,d   Rosé, Jason R ^b,e   Craik, Charles S ^b,c   Böhnlein, Ernst ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SANOFI   (France)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE;

ARTICLE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE MUTATION; GENE THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; VIRUS REPLICATION;

EID: 0029839487     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.70.11.7765-7772.1996     Document Type: Article

References (37)

1. Babé, L. M., S. Pichuantes, and C. S. Craik. 1991. Inhibition of HIV protease activity by heterodimer formation. Biochemistry 30:106-111.
2. Babé, L. M., J. Rosé, and C. S. Craik. 1995. Trans-dominant inhibitory human immunodeficiency virus type 1 protease monomers prevent protease activation and virion maturation. Proc. Natl. Acad. Sci. USA 92:10069-10073.
3. Bahner, I., C. Zhou, X.-J. Yu, Q.-L. Hao, J. C. Guatelli, and D. B. Kohn. 1993, Comparison of trans-dominant inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes. J. Virol. 67:3199-3207.
4. Bevec, D., M. Dobrovnik, J. Hauber, and E. Böhnlein. 1992. Inhibition of human immunodeficiency virus type 1 replication in human T cells by retroviral-mediated gene transfer of a dominant-negative Rev trans-activaior. Proc. Natl. Acad. Sci. USA 89:9870-9874.
5. Buchschacher, G. L., Jr., E. O. Freed, and A. T. Panganiban. 1995. Effects of second-site mutations on dominant interference by a human immunodeficiency virus type 1 envelope glycoprotein mutant. J. Virol. 69:1344-1348.
6. Condra, J. H., W. A. Schleif, O. M. Blahy, L. J. Gadryelski, D. J. Graham, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, D. Titus, T. Yang, H. Teppler, K. E. Squires, P. J. Deutsch, and E. A. Emini. 1995. In vivo emergence of HlV-1 variants resistant to multiple protease inhibitors. Nature (London) 374:569-571.
7. Cullen, B. R. 1991. Regulation of HlV-1 gene expression. FASEB J. 5:2361-2368.
8. Debouck, C., J. G. Gorniak, J. E. Strickler, T. D. Meek, B. W. Metcalf, and M. Rosenberg. 1987. Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor. Proc. Natl. Acad. Sci. USA 84:8903-8906.
9. Ercolani, L., B. Florence, M. Denaro, and M. Alexander. 1988. Isolation and complete sequence of a functional human glyceraldehyde-3-phosphate dehydrogenase gene. J. Biol. Chem. 263:15335-15341.
10. Escaich, S., C. Kalfoglou, I. Plavec, S. Kaushal, J. D. Mosca, and E. Böhnlein. 1995. RevM10-medialed inhibition of HIV-1 replication in chronically infected T cells. Hum. Gene Ther. 6:625-634.
11. Göttlinger, H. G., J. G. Sodroski, and W. A. Haseltine. 1989. Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 86:5781-5785.
12. Jacks, T., M. D. Power, F. R. Masiarz, P. A. Luciw, P. J. Barr, and H. E. Varmus. 1988. Characterization of ribosomal frameshifting in HIV-1 gag/pol expression. Nature (London) 331:280-283.
13. 2 symmetric inhibitors of the human immunodeficiency virus type 1 protease. Antimicrob. Agents Chemother. 35:2209-2214.
14. Kohl, N. E., E. A. Emini, W. A. Schleif, L. J. Davis, J. C. Heimbach, R. A. F. Dixon, E. M. Scolnick, and I. S. Sigal. 1988. Active human immunodeficiency virus type 1 protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA 85:4686-4690.
15. Kräusslich, H. G., and E. Wimmer. 1988. Viral proteinases. Annu. Rev. Biochem. 57:701-754.
16. Leis, J., D. Baltimore, J. M. Bishop, J. Coffin, E. Fleissner, S. P. Goff, S. Oroszlan, H. Robinson, A. M. Skalka, H. M. Temin, and V. Vogt. 1988. Standardized and simplified nomenclature for proteins common to all retroviruses. J. Virol. 62:1808-1809.
17. Leland, D. S, and M. L. V. French. 1988. Virus isolation and identification, p. 39-59. In E. H. Lennette, P. Halonen, and F. A. Murphy (ed.), Laboratory diagnosis of infectious diseases: principles and practice. Springer-Verlag, New York.
18. Levy, J. A., A. D. Hoffman, S. M. Kramer, J. A. Landis, J. M. Shimabukuro, and L. S. Oshiro. 1984. Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science 225:840-842.
19. Malim, M. H., W. W. Freimuth, J. Liu, T. J. Boyle, H. K. Lyerly, B. R. Cullen, and G. J. Nabel. 1992. Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication. J. Exp. Med. 176:1197-1201.
20. Markowitz, M., H. Mo, D. J. Kempf, D. W. Norbeck, T. N. Bhat, J. W. Erickson, and D. D. Ho. 1995. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J. Virol. 69:701-706.
21. Markowitz, M., M. Saag, W. G. Powderly, A. M. Hurley, A. Hsu, J. M. Valdes, D. Henry, F. Sattler, A. La Marca, J. M. Leonard, and D. D. Ho. 1995. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N. Engl. J. Med. 333:1534-1539.
22. McPhee, F., A. C. Good, I. D. Kuntz, and C. S. Craik. Engineering HIV-1 protease heterodimers as macromolecular inhibitors of viral maturation. Proc. Natl. Acad. Sci. USA, in press.
23. McQuade, T, J., A. G. Tomasselli, L. Liu, V. Karacostas, B. Moss, T. K. Sawyer, R. L. Heinrikson, and W. G. Tarpley. 1990. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. Science 247:454-456.
24. Meek, T. D., D. M. Lambert, G. B. Dryer, T. J. Carr, T. A. Tomaszek, Jr., M. L. Moore, J. E. Strickler, C. Debouck, L. J. Hyland, T. J. Matthews, B. W. Metcalf, and S. R. Petteway. 1990. Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues. Nature (London) 343:90-92.
25. Nabel, G. J., B. A. Fox, L. Post, C. B. Thompson, and C. Woffendin. 1994. A molecular genetic intervention for AIDS - effects of a transdominant negative form of Rev. Hum. Gene Ther. 5:79-92.
26. Nara, P. L., and P. J. Fischinger. 1988. Quantitative infectivity assay for HIV-1 and -2. Nature (London) 332:469-470.
27. Page, K. A., N. R. Landau, and D. R. Littman. 1990. Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity. J. Virol. 64:5270-5276.
28. Pearl, L. H., and W. R. Taylor. 1987. A structural model for the retroviral proteases. Nature (London) 329:351-354.
29. Peng, C., B. K. Ho, T. W. Chang, and N. T. Chang. 1989. Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. J. Virol. 63:2550-2556.
30. Ratner, L., A. Fisher, L. L. Jagodzinski, H. Mitsuya, R.-S. Liou, R. C Gallo, and F. Wong-Staal. 1987. Complete nucleotide sequences of functional clones of the AIDS virus. AIDS Res. Hum. Retroviruses 3:57-69.
31. Rigg, R. J., J. S. Dando, S. Escaich, I. Plavec, and E. Böhnlein. 1995. Detection of intracellular HIV-1 rev protein by flow cytometry. J. Immunol. Methods 188:187-195.
32. Rosé, J. R., L. M. Babé, and C. S. Craik. 1995. Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity. J. Virol. 69:2751-2758.
33. Rosen, C. A., J. G. Sodroski, and W. A. Haseltine. 1985. The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat. Cell 41:813-823.
34. Smythe, J. A., D. Sun, M. Thomson, P. D. Markham, M. S. Reitz, Jr., R. C. Gallo, and J. Lisziewicz. 1994. A rev-inducible mutant gag gene stably transferred into T lymphocytes: an approach to gene therapy against human immunodeficiency virus type 1 infection. Proc. Natl. Acad. Sci. USA 91: 3657-3661.
35. Trono, D., M. B. Feinberg, and D. Baltimore. 1989. HIV-1 gag mutants can dominantly interfere with the replication of the wild-type virus. Cell 59:113-120.
36. Wills, J. W., and R. C. Craven. 1991. Form, function, and use of retroviral gag proteins. AIDS 5:639-654.
37. Wlodawer, A., M. Miller, M. Jaskolski, B. K. Sathyanarayana, I. Baldwin, I. T. Weber, L. M. Selk, L. Clawson, J. Schneider, and S. B. H. Kent. 1989. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 245:616-621.